| Year |
Citation |
Score |
| 2024 |
Naqvi AS, Corbett RJ, Seghal P, Conkrite KL, Rathi KS, Ennis BM, Hayer KE, Zhang B, Brown MA, Miller DP, Kraya AA, Dybas JM, Geng Z, Blackden C, Arif S, ... ... Thomas-Tikhonenko A, et al. The splicing modulator is a candidate oncogenic dependency in pediatric high-grade gliomas. Biorxiv : the Preprint Server For Biology. PMID 39149264 DOI: 10.1101/2024.08.03.606419 |
0.793 |
|
| 2024 |
Torres-Diz M, Reglero C, Falkenstein CD, Castro A, Hayer KE, Radens CM, Quesnel-Vallières M, Ang Z, Sehgal P, Li MM, Barash Y, Tasian SK, Ferrando A, Thomas-Tikhonenko A. An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. Cancer Research. PMID 39094066 DOI: 10.1158/0008-5472.CAN-23-3804 |
0.706 |
|
| 2024 |
Torres-Diz M, Reglero C, Falkenstein CD, Castro A, Hayer KE, Radens CM, Quesnel-Vallières M, Ang Z, Sehgal P, Li MM, Barash Y, Tasian SK, Ferrando A, Thomas-Tikhonenko A. An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. Biorxiv : the Preprint Server For Biology. PMID 39091882 DOI: 10.1101/2023.09.14.557413 |
0.706 |
|
| 2023 |
Quesnel-Vallières M, Jewell S, Lynch KW, Thomas-Tikhonenko A, Barash Y. MAJIQlopedia: an encyclopedia of RNA splicing variations in human tissues and cancer. Nucleic Acids Research. PMID 37953365 DOI: 10.1093/nar/gkad1043 |
0.469 |
|
| 2023 |
Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres-Diz M, Xu F, Zankharia U, Zhang Y, Soldan SS, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, ... ... Thomas-Tikhonenko A, et al. Alternative splicing of its 5' UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood. PMID 37683180 DOI: 10.1182/blood.2023020400 |
0.739 |
|
| 2023 |
Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, ... ... Thomas-Tikhonenko A, et al. Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Biorxiv : the Preprint Server For Biology. PMID 37645778 DOI: 10.1101/2023.02.19.529123 |
0.739 |
|
| 2023 |
Wang D, Quesnel-Vallieres M, Jewell S, Elzubeir M, Lynch K, Thomas-Tikhonenko A, Barash Y. A Bayesian model for unsupervised detection of RNA splicing based subtypes in cancers. Nature Communications. 14: 63. PMID 36599821 DOI: 10.1038/s41467-022-35369-0 |
0.491 |
|
| 2022 |
Closa A, Reixachs-Solé M, Fuentes-Fayos AC, Hayer KE, Melero JL, Adriaanse FRS, Bos RS, Torres-Diz M, Hunger SP, Roberts KG, Mullighan CG, Stam RW, Thomas-Tikhonenko A, Castaño JP, Luque RM, et al. A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1. Nar Cancer. 4: zcac041. PMID 36518527 DOI: 10.1093/narcan/zcac041 |
0.71 |
|
| 2022 |
Yang SY, Hayer KE, Fazelinia H, Spruce LA, Asnani M, Black KL, Naqvi AS, Pillai V, Barash Y, Elenitoba-Johnson KSJ, Thomas-Tikhonenko A. FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells. Blood Advances. PMID 36322817 DOI: 10.1182/bloodadvances.2022007910 |
0.817 |
|
| 2022 |
Cortés-López M, Schulz L, Enculescu M, Paret C, Spiekermann B, Quesnel-Vallières M, Torres-Diz M, Unic S, Busch A, Orekhova A, Kuban M, Mesitov M, Mulorz MM, Shraim R, Kielisch F, ... ... Thomas-Tikhonenko A, et al. High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. Nature Communications. 13: 5570. PMID 36138008 DOI: 10.1038/s41467-022-31818-y |
0.39 |
|
| 2022 |
Lee AC, Pingali SR, Pinilla-Ibarz JA, Atchison ML, Koumenis C, Argon Y, Thomas-Tikhonenko A, De Trez C, Hu CA, Tang CA. Loss of AID exacerbates the malignant progression of CLL. Leukemia. PMID 36042317 DOI: 10.1038/s41375-022-01663-5 |
0.327 |
|
| 2022 |
Bagashev A, Sotillo E, Tang CA, Black KL, Perazzelli J, Seeholzer SH, Argon Y, Barrett DM, Grupp SA, Hu CA, Thomas-Tikhonenko A. Correction for Bagashev et al., "CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum". Molecular and Cellular Biology. e0032822. PMID 35976030 DOI: 10.1128/mcb.00328-22 |
0.714 |
|
| 2022 |
Jha A, Quesnel-Vallières M, Wang D, Thomas-Tikhonenko A, Lynch KW, Barash Y. Identifying common transcriptome signatures of cancer by interpreting deep learning models. Genome Biology. 23: 117. PMID 35581644 DOI: 10.1186/s13059-022-02681-3 |
0.47 |
|
| 2022 |
Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, ... ... Thomas-Tikhonenko A, et al. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications. 13: 2228. PMID 35484100 DOI: 10.1038/s41467-022-29669-8 |
0.79 |
|
| 2021 |
Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, ... ... Thomas-Tikhonenko A, et al. Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discovery. PMID 35015683 DOI: 10.1158/2643-3230.BCD-21-0087 |
0.802 |
|
| 2021 |
Sehgal P, Lanauze C, Wang X, Hayer KE, Torres-Diz M, Leu NA, Sela Y, Stanger BZ, Lengner CJ, Thomas-Tikhonenko A. MYC hyperactivates WNT signaling in APC/CTNNB1-mutated colorectal cancer cells through miR-92a-dependent repression of DKK3. Molecular Cancer Research : McR. PMID 34593610 DOI: 10.1158/1541-7786.MCR-21-0666 |
0.667 |
|
| 2021 |
Harrington CT, Sotillo E, Dang CV, Thomas-Tikhonenko A. Tilting MYC toward cancer cell death. Trends in Cancer. PMID 34481764 DOI: 10.1016/j.trecan.2021.08.002 |
0.521 |
|
| 2021 |
Schulz L, Torres-Diz M, Cortés-López M, Hayer KE, Asnani M, Tasian SK, Barash Y, Sotillo E, Zarnack K, König J, Thomas-Tikhonenko A. Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts. Genome Biology. 22: 190. PMID 34183059 DOI: 10.1186/s13059-021-02411-1 |
0.725 |
|
| 2021 |
Slaff B, Radens CM, Jewell P, Jha A, Lahens NF, Grant GR, Thomas-Tikhonenko A, Lynch KW, Barash Y. MOCCASIN: a method for correcting for known and unknown confounders in RNA splicing analysis. Nature Communications. 12: 3353. PMID 34099673 DOI: 10.1038/s41467-021-23608-9 |
0.482 |
|
| 2021 |
Lanauze CB, Sehgal P, Hayer K, Torres-Diz M, Pippin JA, Grant SFA, Thomas-Tikhonenko A. Colorectal cancer-associated Smad4 R361 hotspot mutations boost Wnt/β-catenin signaling through enhanced Smad4-LEF1 binding. Molecular Cancer Research : McR. PMID 33608451 DOI: 10.1158/1541-7786.MCR-20-0721 |
0.649 |
|
| 2020 |
Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, ... ... Thomas-Tikhonenko A, et al. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. PMID 33149299 DOI: 10.1038/s41586-020-2884-6 |
0.324 |
|
| 2019 |
Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein PS, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A. Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. PMID 31758088 DOI: 10.1038/S41375-019-0650-2 |
0.763 |
|
| 2019 |
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances. 3: 3539-3549. PMID 31738832 DOI: 10.1182/Bloodadvances.2019000692 |
0.782 |
|
| 2019 |
Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, ... ... Thomas-Tikhonenko A, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. PMID 31591467 DOI: 10.1038/S41375-019-0580-Z |
0.772 |
|
| 2019 |
Zheng S, Asnani M, Thomas-Tikhonenko A. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors. Cancer Journal (Sudbury, Mass.). 25: 217-222. PMID 31135529 DOI: 10.1097/Ppo.0000000000000381 |
0.551 |
|
| 2019 |
Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein P, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. PMID 30914792 DOI: 10.1038/s41375-019-0454-4 |
0.774 |
|
| 2019 |
Thomas-Tikhonenko A. Dysregulation of splicing factors in B-cell acute lymphoblastic leukemia Biopolymers and Cell. 35: 191-192. DOI: 10.7124/bc.0009c7 |
0.301 |
|
| 2019 |
Zheng S, Naqvi AS, Bolton-Gillespie E, Asnani M, Hayer K, Barash Y, Thomas-Tikhonenko A. Pipeline for Discovering Neoepitopes Generated By Alternative Splicing in B-ALL Blood. 134: 1342-1342. DOI: 10.1182/Blood-2019-131277 |
0.785 |
|
| 2019 |
Li L, Hayer K, Xian L, Luo L, Cope L, Thomas-Tikhonenko A, Resar L. High Mobility Group A1 Chromatin Regulators Function As Critical Drivers of Leukemogenesis in Preclinical Models of Relapsed, Pediatric B-Cell ALL Blood. 134: 3946-3946. DOI: 10.1182/Blood-2019-130261 |
0.741 |
|
| 2019 |
Lee J, Xiao G, Cosgun KNN, Geng H, Ma N, Chan LN, Kume K, Nix M, Chen Z, Chen CD, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, et al. Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis Blood. 134: 2782-2782. DOI: 10.1182/Blood-2019-127615 |
0.446 |
|
| 2019 |
Cai T, Black KL, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Galetto R, Gouble A, Smith JNP, Cavazos A, Han L, Zhang Q, Kuruvilla VM, Ma H, ... ... Thomas-Tikhonenko A, et al. Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease Blood. 134: 2659-2659. DOI: 10.1182/Blood-2019-126869 |
0.643 |
|
| 2018 |
Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A. Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research. PMID 30517739 DOI: 10.1093/nar/gky1231 |
0.78 |
|
| 2018 |
Asnani M, Thomas-Tikhonenko A. Exons of Leukemia Suppressor Genes: Creative Assembly Required. Trends in Cancer. 4: 796-798. PMID 30470300 DOI: 10.1016/J.Trecan.2018.10.005 |
0.351 |
|
| 2018 |
Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A. Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research. PMID 30357359 DOI: 10.1093/Nar/Gky946 |
0.787 |
|
| 2018 |
Bagashev A, Sotillo E, Tang CA, Black KL, Perazzelli J, Seeholzer SH, Argon Y, Barrett DM, Grupp SA, Hu CA, Thomas-Tikhonenko A. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Molecular and Cellular Biology. PMID 30104252 DOI: 10.1128/Mcb.00383-18 |
0.766 |
|
| 2018 |
Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, Rheingold SR, Pillai V. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. American Journal of Hematology. PMID 30058145 DOI: 10.1002/Ajh.25235 |
0.768 |
|
| 2018 |
Thomas-Tikhonenko A. The Impact of Immunotherapy on Tumor Evolution Blood. 132: SCI-18-SCI-18. DOI: 10.1182/Blood-2018-99-109434 |
0.469 |
|
| 2018 |
Cai T, Black KL, Naqvi A, Galetto R, Gouble A, Smith J, Cavazos A, Han L, Zhang Q, Kuruvilla V, Konoplev SNS, Neelapu SS, Lane AA, Guzman ML, Kantarjian H, ... Thomas-Tikhonenko A, et al. Abstract 2560: Preclinical efficacy of allogeneic anti-CD123 CAR T-cells for the therapy of blastic plasmacytoid dendritic cell neoplasm (BPDCN) Cancer Research. 78: 2560-2560. DOI: 10.1158/1538-7445.Am2018-2560 |
0.791 |
|
| 2017 |
Rosenthal J, Naqvi AS, Wertheim G, Paessler M, Rheingold SR, Thomas-Tikhonenko A, Pillai V. Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy Blood. 130: 1331-1331. DOI: 10.1182/Blood.V130.Suppl_1.1331.1331 |
0.47 |
|
| 2016 |
Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, Rheingold SR, Grupp SA, Thomas-Tikhonenko A, Pillai V. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. American Journal of Hematology. PMID 27779774 DOI: 10.1002/Ajh.24594 |
0.386 |
|
| 2016 |
Gennaro V, Zhang X, DeSalle L, Yu D, Thomas-Tikhonenko A, Vakoc C, McMahon SB. Abstract 4553: Identification of CD30/TNFRSF8 as a primary target of the Myc oncoprotein and potential biomarker of Myc-driven cancer Cancer Research. 76: 4553-4553. DOI: 10.1158/1538-7445.Am2016-4553 |
0.5 |
|
| 2015 |
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, ... ... Thomas-Tikhonenko A, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery. PMID 26516065 DOI: 10.1158/2159-8290.Cd-15-1020 |
0.831 |
|
| 2015 |
Bagashev A, Sotillo E, Wu G, Thomas-Tikhonenko A. The Importance of CD19 Exon 2 for Surface Localization: Closing the Ig-like Loop Blood. 126: 3433-3433. DOI: 10.1182/Blood.V126.23.3433.3433 |
0.775 |
|
| 2015 |
Black K, Sotillo E, Martinez N, Gazzara M, Barrera A, Barash Y, Lynch K, Thomas-Tikhonenko A. Regulation of CD19 Exon 2 Inclusion in B-Lymphoid Cells By Splicing Factors and Epigenetic Marks Blood. 126: 2425-2425. DOI: 10.1182/Blood.V126.23.2425.2425 |
0.658 |
|
| 2015 |
Thomas-Tikhonenko A. Abstract IA21: The MYC-microRNA pathway in B-cell neoplasms Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Ia21 |
0.49 |
|
| 2015 |
Sotillo-Piñeiro E, Harrington CT, Jesus DSD, Thomas-Tikhonenko A. Abstract B33: Transient upregulation of Myc with GSK3-β inhibitors in B-cell lymphomas enhances p53-independent apoptotic responses to chemotherapy Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B33 |
0.436 |
|
| 2015 |
Gennaro V, Zhang X, DeSalle L, Yu D, Thomas-Tikhonenko A, McMahon S. Abstract A40: CD30: A therapeutic target of MYC-driven cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A40 |
0.506 |
|
| 2015 |
Sotillo E, Barrett D, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung EY, Hofmann TJ, Maude SL, Martinez NM, Raman P, Ruella M, Allman D, ... ... Thomas-Tikhonenko A, et al. Abstract 3143: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure Cancer Research. 75: 3143-3143. DOI: 10.1158/1538-7445.Am2015-3143 |
0.625 |
|
| 2014 |
Psathas JN, Thomas-Tikhonenko A. MYC and the art of microRNA maintenance. Cold Spring Harbor Perspectives in Medicine. 4. PMID 24737842 DOI: 10.1101/Cshperspect.A014175 |
0.788 |
|
| 2014 |
Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A. Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. Journal of the National Cancer Institute. 106: dju043. PMID 24627270 DOI: 10.1093/Jnci/Dju043 |
0.3 |
|
| 2013 |
Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 122: 4220-9. PMID 24169826 DOI: 10.1182/Blood-2012-12-473090 |
0.793 |
|
| 2013 |
Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A. Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. Rna (New York, N.Y.). 19: 177-90. PMID 23249750 DOI: 10.1261/Rna.036467.112 |
0.559 |
|
| 2013 |
Sotillo-Piñeiro E, Thomas-Tikhonenko A. Abstract 764: Transient up-regulation of Myc in B-cell lymphomas enhances p53-independent apoptotic responses to chemotherapy. Cancer Research. 73: 764-764. DOI: 10.1158/1538-7445.Am2013-764 |
0.436 |
|
| 2012 |
Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, ... Thomas-Tikhonenko A, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. The Journal of Clinical Investigation. 122: 4621-34. PMID 23143306 DOI: 10.1172/Jci62973 |
0.347 |
|
| 2012 |
Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. The Journal of Clinical Investigation. 122: 2257-66. PMID 22546857 DOI: 10.1172/Jci45851 |
0.838 |
|
| 2012 |
Sotillo-Piñeiro E, Xu L, Nguyen L, Laver T, Attiyeh E, Cole K, Diskin S, Maris J, Thomas-Tikhonenko A. Abstract LB-475: 3′UTR polymorphisms affect expression and activity of IGF1R, a therapeutic target in pediatric neuroblastoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-475 |
0.526 |
|
| 2011 |
Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Research. 71: 7490-501. PMID 22028325 DOI: 10.1158/0008-5472.Can-11-1124 |
0.573 |
|
| 2011 |
Zhang XY, Pfeiffer HK, Mellert HS, Stanek TJ, Sussman RT, Kumari A, Yu D, Rigoutsos I, Thomas-Tikhonenko A, Seidel HE, Chodosh LA, Packham G, Baserga R, McMahon SB. Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC. Molecular and Cellular Biology. 31: 5037-45. PMID 21986497 DOI: 10.1128/Mcb.06297-11 |
0.41 |
|
| 2011 |
Sotillo E, Thomas-Tikhonenko A. The long reach of noncoding RNAs. Nature Genetics. 43: 616-7. PMID 21709680 DOI: 10.1038/Ng.870 |
0.304 |
|
| 2011 |
Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, Thomas-Tikhonenko A. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene. 30: 2587-94. PMID 21297663 DOI: 10.1038/Onc.2010.634 |
0.336 |
|
| 2011 |
Koumenis C, Zhang H, Bi M, Lehman SL, Datta T, Liu H, Thomas-Tikhonenko A, Koong A, Fuchs SY, Diehl JA, Ruggero D. Abstract SY06-02: Activation of the UPR by c-Myc promotes transformation and tumorigenesis via cytoprotective autophagy Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy06-02 |
0.368 |
|
| 2011 |
Prema S, Hultine S, Smith L, Biyashev D, Schelter J, Cleary M, Volpert O, Thomas-Tikhonenko A. Abstract 3275: miR-194 counterbalances transcriptional activation of the anti-angiogenic factor thrombospondin-1 by p53 Cancer Research. 71: 3275-3275. DOI: 10.1158/1538-7445.Am2011-3275 |
0.321 |
|
| 2010 |
Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Molecular Cell. 40: 762-73. PMID 21145484 DOI: 10.1016/J.Molcel.2010.11.038 |
0.309 |
|
| 2010 |
Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Research. 70: 8233-46. PMID 20940405 DOI: 10.1158/0008-5472.Can-10-2412 |
0.634 |
|
| 2010 |
Hart LS, Finnberg N, Dolloff NG, Rodgers ZB, Dicker DT, Thomas-Tikhonenko A, El-Deiry WS. Abstract 4326: High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors Cancer Research. 70: 4326-4326. DOI: 10.1158/1538-7445.Am10-4326 |
0.474 |
|
| 2009 |
Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A. Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Advances in Cancer Research. 105: 115-32. PMID 19879426 DOI: 10.1016/S0065-230X(09)05007-6 |
0.322 |
|
| 2009 |
Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. Journal of the National Cancer Institute. 101: 663-77. PMID 19401549 DOI: 10.1093/Jnci/Djp063 |
0.343 |
|
| 2009 |
Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, Thomas-Tikhonenko A, Mendella JT. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation Proceedings of the National Academy of Sciences of the United States of America. 106: 3384-3389. PMID 19211792 DOI: 10.1073/Pnas.0808300106 |
0.565 |
|
| 2008 |
Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC, Schelter JM, Cleary MA, Mendell JT, Thomas-Tikhonenko A. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biology & Therapy. 7: 1758-64. PMID 18708755 DOI: 10.4161/Cbt.7.11.6722 |
0.614 |
|
| 2008 |
Thomas-Tikhonenko A, Cozma D. PAX5 and B-cell neoplasms: transformation through presentation. Future Oncology (London, England). 4: 5-9. PMID 18240995 DOI: 10.2217/14796694.4.1.5 |
0.424 |
|
| 2008 |
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Widespread microRNA repression by Myc contributes to tumorigenesis Nature Genetics. 40: 43-50. PMID 18066065 DOI: 10.1038/Ng.2007.30 |
0.683 |
|
| 2007 |
Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, Ahmad N, Spiegelman VS. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Research. 67: 10642-6. PMID 18006803 DOI: 10.1158/0008-5472.Can-07-2015 |
0.308 |
|
| 2007 |
Kumar KG, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biology & Therapy. 6: 1437-41. PMID 17873516 DOI: 10.4161/Cbt.6.9.4569 |
0.36 |
|
| 2007 |
Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, Metzgar MH, Paterson J, Erikson J, Marafioti T, Monroe JG, Atchison ML, Thomas-Tikhonenko A. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. The Journal of Clinical Investigation. 117: 2602-10. PMID 17717600 DOI: 10.1172/Jci30842 |
0.492 |
|
| 2007 |
Yu D, Carroll M, Thomas-Tikhonenko A. p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood. 109: 4936-43. PMID 17284530 DOI: 10.1182/Blood-2006-10-050294 |
0.359 |
|
| 2007 |
Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. The Journal of Clinical Investigation. 117: 326-36. PMID 17235397 DOI: 10.1172/Jci28833 |
0.363 |
|
| 2007 |
Hodawadekar S, Yu D, Cozma D, Freedman B, Sunyer O, Atchison ML, Thomas-Tikhonenko A. B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. Experimental Cell Research. 313: 331-40. PMID 17098231 DOI: 10.1016/J.Yexcr.2006.10.015 |
0.444 |
|
| 2007 |
Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY. Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells Oncogene. 26: 1954-1958. PMID 17001349 DOI: 10.1038/Sj.Onc.1209994 |
0.371 |
|
| 2007 |
Chung EY, Cozma D, Yu D, Dews M, Wentzel EA, Chang T, Mendell JT, Thomas-Tikhonenko A. Pax5 Activates Oncogenic Transcription Factors of the Ets Family by Repressing the mir-15a/16-1 microRNA Cluster. Blood. 110: 346-346. DOI: 10.1182/Blood.V110.11.346.346 |
0.644 |
|
| 2006 |
Hodawadekar S, Wei F, Yu D, Thomas-Tikhonenko A, Atchison ML. Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. Journal of Immunology (Baltimore, Md. : 1950). 177: 6165-71. PMID 17056545 DOI: 10.4049/Jimmunol.177.9.6165 |
0.445 |
|
| 2006 |
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genetics. 38: 1060-5. PMID 16878133 DOI: 10.1038/Ng1855 |
0.627 |
|
| 2006 |
Cozma D, Thomas-Tikhonenko A. Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemia. Cancer Biology & Therapy. 5: 579-81. PMID 16760643 DOI: 10.4161/Cbt.5.6.2873 |
0.375 |
|
| 2006 |
O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, Dang CV. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis Molecular and Cellular Biology. 26: 2373-2386. PMID 16508012 DOI: 10.1128/Mcb.26.6.2373-2386.2006 |
0.586 |
|
| 2006 |
Bertout J, Thomas-Tikhonenko A. Infection & Neoplastic Growth 101 Cancer Treatment and Research. 130: 167-197. DOI: 10.1007/0-387-26283-0_8 |
0.366 |
|
| 2005 |
Yu D, Cozma D, Park A, Thomas-Tikhonenko A. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Annals of the New York Academy of Sciences. 1059: 145-59. PMID 16382050 DOI: 10.1196/annals.1339.047 |
0.347 |
|
| 2005 |
Zhang XY, DeSalle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, McMahon SB. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proceedings of the National Academy of Sciences of the United States of America. 102: 13968-73. PMID 16172399 DOI: 10.1073/Pnas.0502330102 |
0.343 |
|
| 2005 |
Yu D, Dews M, Park A, Tobias JW, Thomas-Tikhonenko A. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Research. 65: 5454-61. PMID 15958595 DOI: 10.1158/0008-5472.Can-04-4197 |
0.519 |
|
| 2005 |
Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY. Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Research. 65: 1904-8. PMID 15753389 DOI: 10.1158/0008-5472.Can-04-2597 |
0.302 |
|
| 2005 |
Amaravadi RK, Yu D, Thomas-Tikhonenko A, Thompson CB. Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma. Blood. 106: 2421-2421. DOI: 10.1182/Blood.V106.11.2421.2421 |
0.381 |
|
| 2004 |
Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Molecular and Cellular Biology. 24: 8541-55. PMID 15367674 DOI: 10.1128/Mcb.24.19.8541-8555.2004 |
0.511 |
|
| 2004 |
Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Research. 64: 3126-36. PMID 15126350 DOI: 10.1158/0008-5472.Can-03-1953 |
0.524 |
|
| 2003 |
Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood. 101: 1950-5. PMID 12406913 DOI: 10.1182/Blood-2002-06-1797 |
0.496 |
|
| 2002 |
Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene. 21: 1922-7. PMID 11896625 DOI: 10.1038/Sj.Onc.1205244 |
0.456 |
|
| 2001 |
Yu D, Thomas-Tikhonenko A. Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism Cancer Letters. 173: 145-154. PMID 11597789 DOI: 10.1016/S0304-3835(01)00612-7 |
0.398 |
|
| 2001 |
Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, Golovkina TV, Evans S, Lee WF, Thomas-Tikhonenko A. Cutting edge: Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis Journal of Immunology. 166: 5878-5881. PMID 11342601 DOI: 10.4049/Jimmunol.166.10.5878 |
0.304 |
|
| 2000 |
Janz A, Sevignani C, Kenyon K, Ngo CV, Thomas-Tikhonenko A. Activation of the Myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA Nucleic Acids Research. 28: 2268-2275. PMID 10871348 DOI: 10.1093/Nar/28.11.2268 |
0.367 |
|
| Show low-probability matches. |